FLHLF News and Press, Filament Health From 09/22/22

TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary o...

FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL Canada NewsWire Subjects were given Filament's psilocybin drug candidate in the first Canadian trial with the purpose of psychedelic therapist traini...

Filament Health press release ( OTCQB:FLHLF ): Q2 Cash and cash equivalents of C$3.0M as of June 30, 2022. For further details see: Filament Health reports Q2 results

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL Canada NewsWire VANCOUVER, BC , Aug. 24, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical...

FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds and strengthens Filament's industry-leading IP portfolio VANCOUVER, BC , Aug. 17, 2022 ...

The emerging psychedelics industry is stuck with a sort of default business model that goes something like this: build a team of entrepreneurial-minded C-suite people, add a few qualified medical people, get a patented psychedelic molecule or compound to test and develop, build ...

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , Aug. 15, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-st...

FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE Canada NewsWire The newly-launched program, led by Canadian non-profit TheraPsil, is the world's largest medical psilocybin access and data project VANCOUVER, BC , July 28, 2022 /CNW/...

Recent Progress Has Been Made In Several Areas. Filament Health has announced the dosing of the first patient in the Phase 1 trial testing orally administered psilocybin against its two formulations of psilocin. This trial will compare psilocybin with two proprietary formulations of psilocin, ...

FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT Canada NewsWire Financing led by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex VANCOUVER, BC , July 13, 2022 /CNW/ - Filament Hea...